---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-058638"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-05-11T20:05:49+00:00"
generated_at: "2026-05-11T22:45:23.688055+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026

## Summary
- Net loss of $43.3M for Q1 2026 versus $64.4M in Q1 2025; R&D expenses $37.6M (down 39% YoY).
- Cash and investments $326.4M as of March 31, 2026, expected to fund operations into 4Q 2027.
- Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected mid-2026.
- FDA IND clearance for ARR-002 (MUC16/NaPi2b dual-target tetravalent ADC) for ovarian/endometrial cancers; first patient dosing in 2H 2026.
- ARR-217 (CDH17 ADC) first patient dosed March 2026; dose escalation ongoing for gastrointestinal malignancies.

## SEC filing metadata
- accession: 0001104659-26-058638
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-05-11T20:05:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/0001104659-26-058638-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-058638
- JSON: https://secwatch.observer/filing/0001104659-26-058638.json
- Plain text: https://secwatch.observer/filing/0001104659-26-058638.txt

## Key facts
- Earnings Releases
  ArriVent BioPharma, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively..
  - Period: first quarter ended March 31, 2026
  - Net income: Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively.
  - Result: reported results
  source text: Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/0001104659-26-058638-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.